Tempus AI (NASDAQ:TEM) Price Target Lowered to $55.00 at Piper Sandler

Tempus AI (NASDAQ:TEM) had its target price cut by Piper Sandler from $70.00 to $55.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research analysts have also recently issued reports on TEM. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Bank of America increased their target price on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday. TD Cowen reiterated a “buy” rating and set a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Needham & Company LLC raised their price objective on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $59.73.

Tempus AI Trading Up 3.5 %

Shares of NASDAQ:TEM opened at $52.73 on Tuesday. Tempus AI has a 12 month low of $22.89 and a 12 month high of $91.45. The stock’s 50 day moving average price is $53.02 and its 200 day moving average price is $52.55. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Transactions at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 13,770 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the sale, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at $3,434,220. This trade represents a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.75, for a total value of $190,363,747.50. Following the sale, the chief executive officer now directly owns 4,895,589 shares of the company’s stock, valued at $287,615,853.75. This trade represents a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,823,701 shares of company stock valued at $320,906,059 in the last three months.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI in the 3rd quarter valued at approximately $1,367,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tempus AI in the 4th quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Tempus AI in the 4th quarter valued at approximately $178,000. Finally, Captrust Financial Advisors bought a new position in shares of Tempus AI in the 3rd quarter valued at approximately $2,726,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.